-
Dr. Youwen Tan: Baseline Hepatocyte Ballooning is a Risk Factor for the Evolution of Non-Alcoholic Fatty Liver Disease in Chronic Hepatitis B
Chronic hepatitis B (CHB) and non-alcoholic fatty liver disease (NAFLD) are both significant contributors to liver-related complications and mortality. Dr. Youwen Tan’s team at the Third People’s Hospital of Jiangsu…
-
Dr. Chao Wu/ Dr. Jie Li/ Dr. Rui Huang’s Team: 14 Studies Selected for Presentation on Conference, 3 Studies Receive Young Researcher Awards, Abundant Achievements!
Doctor Chao Wu’s team from the Department of Infectious Diseases, Nanjing Medical University Affiliated Drum Tower Hospital in China, has long been committed to clinical and basic research with a…
-
Dr. Qin Ning’s Team: Focus on Hepatitis B, Fatty Liver, Liver Injury, and End-Stage Liver Disease, Unveiling 8 Achievements at the AASLD Meeting
From November 10th to 14th, 2023, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2023) was grandly held in Boston, USA. Dr. Qin Ning’s team from Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, presented 2 posters of distinction and 6 posters on scientific research in…
-
Dr. Xuefeng Luo’s Team: Poor Prognosis for Acute Variceal Bleeding with Liver Cancer, Liver Function Grading and Tumor Staging as Major Risk Factors
From November 10th to 14th, 2023, the annual highlight of the liver disease field, the American Association for the Study of Liver Diseases (AASLD) Annual Meeting 2023, was grandly held in Boston, USA. Several research achievements from Dr. Xuefeng Luo’s team at West China Hospital of Sichuan University were included in the conference [1-3], with…
-
Breakthrough in Clinical Treatment of Chronic Drug-Induced Liver Injury: Optimizing Steroid Regimen and Indications – A Voice from AASLD China
Recently, the Liver Disease Department and Pathology Department at the Fifth Medical Center of the People’s Liberation Army General Hospital (formerly the PLA Third O2 Hospital) collaborated to achieve a new breakthrough in the clinical treatment of Chronic Drug-Induced Liver Injury (DILI). The research teams, led by Dr. Zhengsheng Zou, Jingmin Zhao, and Dong Ji,…
-
Doctor Raluca Pais: Weight Loss Therapy is the Cornerstone of NAFLD Management
Fatty liver disease has become the most prevalent liver condition worldwide and a hot topic at the 58th Annual Meeting of the European Association for the Study of the Liver…
-
Doctor Tarik Asselah: Beyond Liver Cancer, Viral Hepatitis Is Also Linked to Some Extrahepatic Malignancies
At the 58th Annual Meeting of the European Association for the Study of the Liver (EASL 2023) and the EASL Congress 2023, Doctor Tarik Asselah from Paris University and Beaujon…
-
Doctor Thomas Reiberger: Hotly Debated Issues on the Use of Non-Selective Beta-Blockers (NSBBs) in the Treatment of Cirrhosis
🔍 Exploring the Complexities of Cirrhosis Treatment: Insights from Dr. Thomas Reiberger Welcome to the latest feature from Hepatology Digest, where we delve into the nuanced world of liver health. In our upcoming article, we’re excited to present the esteemed Dr. Thomas Reiberger, a leading figure in hepatology, known for his extensive research and clinical…
Connecting Medical Expertise through Media